Discover how BioDuro’ s integrated drug discovery platform accelerated a novel kinase inhibitor for inflammatory disease from initial hit identification to preclinical candidate (PCC) in just 16 months. This case study highlights our streamlined approach, combining medicinal chemistry, biology, and DMPK under one roof to deliver efficiency, collaboration, and rapid progress.

Key Highlights

• Speed to PCC: Achieved in 16 months through optimized workflows and parallel processes.
• End-to-End Integration: All services executed at a single site, eliminating logistical delays.
• Efficient Scaling: Synthesized and tested 400+ compounds, ensuring robust SAR and selectivity.
• Streamlined Coordination: Weekly meetings with team leaders and a dedicated project manager ensured progress.

Download the full case study to learn how BioDuro accelerates drug discovery from hit to PCC.